Detailansicht

Wissensnetz

Person

Tjalf Ziemssen (1973-)

Name	Tjalf Ziemssen
Zeit	1973- (Lebensdaten)
Akademischer Grad bzw. Titel	Dr.
Weitere Angaben	Tätig am Universitätsklinikum Dresden, Leiter MS Zentrum (Multiple Sklerose), Neurologische Uniklinik Dresden; Diss. Fachbereich Humanmedizin
Datensatztyp	Person
GND-Nummer	121317315
Datensatz-ID	121317315
Beteiligt an alle anzeigen MS brain health quality standards: a survey on the reality in clinical practice in Germany Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing–Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study Serum neurofilament indicates accelerated neurodegeneration and predicts mortality in late-stage Parkinson’s disease Neue Therapieansätze bei Multipler Sklerose inkl. Stellenwert älterer Präparate Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury Die Generation Alpha der Digital Health Innovationen – Eine Fallstudie aus der Multiple Sklerose Versorgung Differential effects of selective versus unselective sphingosine 1-phosphate receptor modulators on T- and B-cell response to SARS-CoV-2 vaccination Influence of exercise on quantity and deformability of immune cells in multiple sclerosis Long‑term real‑world effectiveness and safety of fingolimod over 5 years in Germany NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines Phenotyping of multiple sclerosis patients through clinical and paraclinical resources Pilot study on the influence of acute alcohol exposure on biophysical parameters of leukocytes S1P receptor modulators and the cardiovascular autonomic nervous system in multiple sclerosis : a narrative review Serum neurofilament indicates that DBS surgery can cause neuronal damage whereas stimulation itself does not The need for a strategic therapeutic approach : multiple sclerosis in check Ambulante spezialfachärztliche Versorgung (ASV) für die multiple Sklerose : Positionspapier der Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) auf der Basis gegenwärtiger Versorgungsdefizite und -hürden („white paper“) Can ChatGPT explain it? Use of artificial intelligence in multiple sclerosis communication Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis Neue Therapieansätze bei Multipler Sklerose inkl. Stellenwert älterer Präparate Antigen-specific depletion of autoreacitve B cells in multiple sclerosis Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline Classifying flow cytometry data using Bayesian analysis helps to distinguish ALS patients from healthy controls Entwicklung und Validierung einer Serious Gaming-Anwendung für die Komplikationsfrüherkennung und das Komplikationsmanagement nach viszeralchirurgischen Eingriffen Polypharmacy in patients with multiple sclerosis and the impact on levels of care and therapy units Erratum zu: Die Generation Alpha der Digital Health Innovationen – Eine Fallstudie aus der Multiple Sklerose Versorgung Die Generation Alpha der Digital Health Innovationen – Eine Fallstudie aus der Multiple Sklerose Versorgung Comprehensive proteomic profiling of serum extracellular vesicles in patients with colorectal liver metastases identifies a signature for non-invasive risk stratification and early-response evaluation Neuer Masterstudiengang: Multiple Sklerose Management Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany Evaluation der langfristigen klinischen und ökonomischen Auswirkungen einer Behandlung mit Ofatumumab gegenüber Dimethylfumarat und Glatirameracetat bei Patienten mit schubförmiger Multipler Sklerose aus gesellschaftlicher Sicht in Deutschland Der Multiple Sclerosis Health Resource Utilization Survey Charakterisierung von Neurofilament-Leichtketten als Serum-basierter Biomarker bei der Spinalen Muskelatrophie im Kindesalter mittels hochsensitiver Messverfahren International consensus on quality standards for brain health-focused care in multiple sclerosis Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis Daten sammeln aus der Praxis: der Weg zum digitalen MS-Zwilling Die Neurodegeneration an den Augen ablesen Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper) Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis MSProDiscuss – Entwicklung eines digitalen Tools zur standardisierten Patientenanamnese, um Progredienz bei Multipler Sklerose zu identifizieren MS-Monitoring mit molekularen Biomarkern - wo stehen wir? Impedimetric Microfluidic Sensor‐in‐a‐Tube for Label‐Free Immune Cell Analysis Der Einfluss der Schädigung der grauen Substanz auf die klinische Beeinträchtigung bei Patient*innen mit Multipler Sklerose Impedimetric Microfluidic Sensor-in-a-Tube for Label-Free Immune Cell Analysis Mechanische und metabolische Phänotypisierung peripherer Immunzellen als mögliche zellbasierte Biomarker in der Charakterisierung von Multiple Sklerose Patienten Der Patient als Experte Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study Was die Schritte verraten Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies Correction to: Real-World Evidence on the Patterns of Increased Societal Economic Relapse Costs in Patients with Multiple Sclerosis Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis Schübe und Progression der MS klinisch beurteilen Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study Correction to: Differentiating societal costs of disability worsening in multiple sclerosis Effects of the Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone on Peripheral Vessel Function and Clinical Parameters in Nondiabetic Patients : A Double-Center, Randomized Controlled Pilot Trial The societal economic costs of disability worsening and relapses in patients with multiple sclerosis : Die gesellschaftlichen Kosten von Behinderungsprogression und Schüben bei Patienten mit Multipler Sklerose Molecular biomarkers in multiple sclerosis Differentiating societal costs of disability worsening in multiple sclerosis Clinical relevance of circadian melatonin release in relapsing-remitting multiple sclerosis A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Tjalf Ziemssen (1973-)

MS brain health quality standards: a survey on the reality in clinical practice in Germany

Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing–Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study

Serum neurofilament indicates accelerated neurodegeneration and predicts mortality in late-stage Parkinson’s disease

Neue Therapieansätze bei Multipler Sklerose inkl. Stellenwert älterer Präparate

Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury

Die Generation Alpha der Digital Health Innovationen – Eine Fallstudie aus der Multiple Sklerose Versorgung

Differential effects of selective versus unselective sphingosine 1-phosphate receptor modulators on T- and B-cell response to SARS-CoV-2 vaccination

Influence of exercise on quantity and deformability of immune cells in multiple sclerosis

Long‑term real‑world effectiveness and safety of fingolimod over 5 years in Germany

NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines

Phenotyping of multiple sclerosis patients through clinical and paraclinical resources

Pilot study on the influence of acute alcohol exposure on biophysical parameters of leukocytes

S1P receptor modulators and the cardiovascular autonomic nervous system in multiple sclerosis : a narrative review

Serum neurofilament indicates that DBS surgery can cause neuronal damage whereas stimulation itself does not

The need for a strategic therapeutic approach : multiple sclerosis in check

Ambulante spezialfachärztliche Versorgung (ASV) für die multiple Sklerose : Positionspapier der Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) auf der Basis gegenwärtiger Versorgungsdefizite und -hürden („white paper“)

Can ChatGPT explain it? Use of artificial intelligence in multiple sclerosis communication

Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ponesimod, and Teriflunomide for Relapsing Multiple Sclerosis

Neue Therapieansätze bei Multipler Sklerose inkl. Stellenwert älterer Präparate

Antigen-specific depletion of autoreacitve B cells in multiple sclerosis

Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline

Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline

Classifying flow cytometry data using Bayesian analysis helps to distinguish ALS patients from healthy controls

Entwicklung und Validierung einer Serious Gaming-Anwendung für die Komplikationsfrüherkennung und das Komplikationsmanagement nach viszeralchirurgischen Eingriffen

Polypharmacy in patients with multiple sclerosis and the impact on levels of care and therapy units

Erratum zu: Die Generation Alpha der Digital Health Innovationen – Eine Fallstudie aus der Multiple Sklerose Versorgung

Die Generation Alpha der Digital Health Innovationen – Eine Fallstudie aus der Multiple Sklerose Versorgung

Comprehensive proteomic profiling of serum extracellular vesicles in patients with colorectal liver metastases identifies a signature for non-invasive risk stratification and early-response evaluation

Neuer Masterstudiengang: Multiple Sklerose Management

Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany

Evaluation der langfristigen klinischen und ökonomischen Auswirkungen einer Behandlung mit Ofatumumab gegenüber Dimethylfumarat und Glatirameracetat bei Patienten mit schubförmiger Multipler Sklerose aus gesellschaftlicher Sicht in Deutschland

Der Multiple Sclerosis Health Resource Utilization Survey

Charakterisierung von Neurofilament-Leichtketten als Serum-basierter Biomarker bei der Spinalen Muskelatrophie im Kindesalter mittels hochsensitiver Messverfahren

International consensus on quality standards for brain health-focused care in multiple sclerosis

Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis

Daten sammeln aus der Praxis: der Weg zum digitalen MS-Zwilling

Die Neurodegeneration an den Augen ablesen

Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper)

Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis

MSProDiscuss – Entwicklung eines digitalen Tools zur standardisierten Patientenanamnese, um Progredienz bei Multipler Sklerose zu identifizieren

MS-Monitoring mit molekularen Biomarkern - wo stehen wir?

Impedimetric Microfluidic Sensor‐in‐a‐Tube for Label‐Free Immune Cell Analysis

Der Einfluss der Schädigung der grauen Substanz auf die klinische Beeinträchtigung bei Patient*innen mit Multipler Sklerose

Impedimetric Microfluidic Sensor-in-a-Tube for Label-Free Immune Cell Analysis

Mechanische und metabolische Phänotypisierung peripherer Immunzellen als mögliche zellbasierte Biomarker in der Charakterisierung von Multiple Sklerose Patienten

Der Patient als Experte

Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study

Was die Schritte verraten

Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies

Correction to: Real-World Evidence on the Patterns of Increased Societal Economic Relapse Costs in Patients with Multiple Sclerosis

Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis

Schübe und Progression der MS klinisch beurteilen

Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study

Correction to: Differentiating societal costs of disability worsening in multiple sclerosis

Effects of the Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone on Peripheral Vessel Function and Clinical Parameters in Nondiabetic Patients : A Double-Center, Randomized Controlled Pilot Trial

The societal economic costs of disability worsening and relapses in patients with multiple sclerosis : Die gesellschaftlichen Kosten von Behinderungsprogression und Schüben bei Patienten mit Multipler Sklerose

Molecular biomarkers in multiple sclerosis

Differentiating societal costs of disability worsening in multiple sclerosis

Clinical relevance of circadian melatonin release in relapsing-remitting multiple sclerosis

A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition